Drug Trial Radar · NCT02536937
A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
Last checked: Nov 19, 2026Latest source record: Mar 8, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Sep 2015
Primary completion
Jan 2017
Study completion Jan 2017
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 1, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary Objective: To study the effect of mild, moderate, and severe renal impairment on the pharmacokinetics (PK) of eliglustat. Secondary Objective: To assess the tolerability of eliglustat tartrate given as a single dose in subjects with mild, moderate, and severe renal impairment in comparison with matched subjects with normal renal function.
Conditions
- Gaucher Disease
Interventions
eliglustatDrug
Pharmaceutical form: capsule Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- - Assessment of PK parameter: Maximum plasma concentration observed (Cmax)Time frame: 3 days
- - Assessment of PK parameter: Area under the plasma concentration (AUC)Time frame: 3 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number 840004
Miami, Florida
Investigational Site Number 840002
Saint Paul, Minnesota
Investigational Site Number 840001
Knoxville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.